However, in this study, it is higher than the reported in studies made with adults, and it can give information for the understanding of the immunity to COVID-19 in the long term. Pneumonia was associated with severe disease (<0,01) however, in most cases, antibodies were not detected (p=0,015).Ĭonclusion: The duration of antibodies after the infection by SARS-CoV-2 in pediatric age remains unknown. Three of those patients had a chronic disease. As for severity, 10% had mild disease, 50% moderate, 30% severe and 10% critical. The rest of 20/45 were symptomatic patients, and their diagnosis were pneumonia (13), COVID-19 (5), small infant sepsis (1) and CNS disease (1). 25/45 were asymptomatic and hospitalized for another pathology. Of the 45/207 (21,7%) patients who did not develop antibodies, the median age was 5 years (min 21 days max 18 years), and 62% were male. The antibodies were detected with a median of 4 months post-infection (min 1 month max 13 months). 30% of these had a chronic disease, and 4,4% were on immunosuppressants. Of these 91 symptomatic cases, 9% had mild disease, 40% moderate, 15% severe and 36% critical.

The remaining 91 of 162 cases were symptomatic, and the diagnosis was multisystemic inflammatory syndrome associated with COVID-19 (MIS-C) (17,9%), COVID-19 (16%), pneumonia (13,6%), small infant sepsis (5%), CNS disease (2,3%) and myocarditis (1,2%). 71/162 (43,8%) were asymptomatic and hospitalized for another pathology. The median age was 6 years (min 13 days max 17 years), 60% were male. Results: From a total of 207 patients, 162 (78,3%) developed SARS-CoV-2 antibodies. The method used was electrochemiluminescence with the reagent Elecsys® Anti SARS-CoV-2 from Roche.

Methods: Descriptive study of the serological condition of patients under 18 after their hospitalization due to COVID-19, from April 2020 to May 2021. However, the results in pediatric age are limited, and the immune response to the virus is poorly known.Īim: Evaluate the serological response of hospitalized patients suffering from SARS-CoV-2 in a tertiary pediatric hospital. Introduction: When the pandemic started, the serological tests for SARS-CoV-2 were quickly developed. Vasconcelos, Joana 1 Matos, Vitória 2 Brito, Maria João 1ġPediatric Infectious Diseases Unit, Hospital Dona Estefânia, CHULC, Portugal 2Immunology and Infectious Serology Department, CHULC, Lisbon, Portugal Serological tests for post SARS-COV-2 infection in pediatric age Keywords: COVID-19, SARS-CoV-2 antibodies, Pediatric age

Black tongue nadir 320